Noble Financial Downgrades Anadys Pharmaceuticals (ANDS) to Sell
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 34
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 34
Join SI Premium – FREE
Noble Financial downgraded Anadys Pharmaceuticals (NASDAQ: ANDS) from Buy to Sell, maintains price target of $3.50.
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Shares of Anadys Pharmaceuticals closed at $3.65 yesterday.
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Shares of Anadys Pharmaceuticals closed at $3.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades BOK Financial (BOKF) to Underweight
- Barclays Downgrades Mobileye N.V (MBLY) to Equalweight
- Goldman Sachs Upgrades TC Energy (TRP:CN) (TRP) to Buy
Create E-mail Alert Related Categories
DowngradesRelated Entities
Noble FinancialSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
